Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (31-40 of 755) with videos related to

Pageof 76
Sort By:
Agents and Actions. Supplements|January 1, 1985
Significance of NSAID serum to response relationshipsD E Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Journal of Clinical Pharmacology|June 1, 1988
Comments on possible long-term consequences of nonsteroidal anti-inflammatory useD E Furst
The Journal of Rheumatology|August 4, 2004
Observational cohort studies and well controlled clinical trials--we need them both!Daniel E Furst
The Journal of Rheumatology. Supplement|March 1, 1996
Clinical pharmacology of combination DMARD therapy in rheumatoid arthritisD E Furst
Current Opinion in Rheumatology|May 1, 2002
Stem cell transplantation for autoimmune disease: progress and problemsDaniel E Furst
The American Journal of Medicine|July 13, 1984
Use of ibuprofen in unusual circumstancesD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1997
Meloxicam: selective COX-2 inhibition in clinical practiceD E Furst
Pageof 76

Showing results (31-40 of 755) with videos related to

Sort By:
Pageof 76
Agents and Actions. Supplements|January 1, 1985
Significance of NSAID serum to response relationshipsD E Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Journal of Clinical Pharmacology|June 1, 1988
Comments on possible long-term consequences of nonsteroidal anti-inflammatory useD E Furst
The Journal of Rheumatology|August 4, 2004
Observational cohort studies and well controlled clinical trials--we need them both!Daniel E Furst
The Journal of Rheumatology. Supplement|March 1, 1996
Clinical pharmacology of combination DMARD therapy in rheumatoid arthritisD E Furst
Current Opinion in Rheumatology|May 1, 2002
Stem cell transplantation for autoimmune disease: progress and problemsDaniel E Furst
The American Journal of Medicine|July 13, 1984
Use of ibuprofen in unusual circumstancesD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1997
Meloxicam: selective COX-2 inhibition in clinical practiceD E Furst
Pageof 76